Background: Folliculotropic mycosis fungoides (FMF) is a distinct variant of mycosis
| INTRODUCTION

Folliculotropic mycosis fungoides (FMF) is recognized as a distinct variant of mycosis fungoides (MF). FMF is histopathologically charac-
terized by the presence of folliculotropic infiltrates consisting of atypical, T-cells, that often spare the epidermis. [1] [2] [3] Clinically, skin lesions are preferentially located in the head and neck region and are frequently accompanied by local alopecia, and may include (grouped) follicular papules, acneiform and cystic lesions, plaques and tumors and in some patients keratosis pilaris-like skin lesions, which are located preferentially on the extremities or trunk. Factors significant in univariate analysis were included in a multivariate analysis model. In both models, P-values below 0.05 were considered significant.
| RESULTS
| Clinical characteristics
The study included 29 males and 11 females (ratio: 2.6) with a median age at diagnosis of 56 years (range: 19-82 years). Distinction was made between patients with disease progression (P-FMF) and patients without disease progression for at least 5 years after diagnosis (NP-FMF). In the P-FMF group, the median time from diagnosis to disease progression was 30 months (range, 3-136 months) and occurred within 5 years after diagnosis in 17 of 20 patients and after 61, 66, and 136 months in the other three patients. The main clinical characteristics of these two groups are presented in Table 1 .
The median age at diagnosis of patients in the P-FMF group was higher than in the NP-FMF group (62 vs 51 years, respectively, P = 0.004). No significant differences between the P-FMF group and the NP-FMF group were found in the extent of skin lesions, the predominant involvement of the head and neck region, the presence of pruritus, and the initial type of treatment. The number of patients achieving complete remission upon initial treatment was higher in the NP-FMF group than in the P-FMF group (60% vs 15%, respectively, P = 0.003), but overall response rates were comparable (75% vs 65%, respectively). 
| Histopathology
The main histopathological findings in these 40 patients with plaque stage FMF are summarized in Table 2 . In 35 of 40 cases, biopsies were obtained from skin lesions in the head and neck area. In two cases of the NP-FMF group and three cases of the P-FMF group, skin lesions on the back (four cases) or arm (one case) were biopsied.
Twenty cases showed sparse (n = 4) or prominent (n = 14) infiltrates confined to the perifollicular area (Figures 1 and 2 ). Confluent perifollicular and perivascular infiltrates or completely diffuse infiltrates were observed in the other 22 cases, and were more common in the P-FMF group (Figures 3 and 4) . infiltrates were less than 10% in seven cases, 10% to 25% in 12 cases and more than 25% in 21 cases. Percentages above 25%
were more frequent in the P-FMF than in the NP-FMF group (75% vs 30%, respectively; P = 0.02). In 33 of 40 cases (83%), these atypical cells were predominantly small to medium-sized ( Figures 2B and 4A ). In the other seven cases, all seven belonging to the P-FMF group, they were predominantly medium-sized to large ( Figure 3C ). Blast cells were either few or absent in 34 of 40 cases (85%). In six cases, they made up more than 10% of the T-cell infiltrate, but only three cases had percentages more than 25% and were considered to show large cell transformation. 16 The neoplastic cells had a CD3+, CD4+, CD8-T-cell phenotype in 38 cases and a CD3+, CD4-, CD8+ T-cell phenotype in two cases. Expression of CD30 by more than 10% of the neoplastic T-cells was observed in two of 20 cases (10%) in the NP-FMF group and five of 20 cases (25%) in the P-FMF group. Percentages of more than 10% Ki-67 positive cells were detected in 11 of 40 cases and were much more common in the P-FMF group than in the NP-FMF group (50% and 5%, respectively P = <0.01) ( Figure 3E ). Dermal infiltrates contained variable numbers of admixed inflammatory cells, but comparison of the two subgroups of plaque stage FMF showed no significant differences. Percentages of admixed CD8+
T-cells varied between 10% to more than 25% in 20 cases with a CD4+
T-cell phenotype, while percentages lower than 10% were found in 
| Prognostic factors
Factors that significantly correlated with both disease progression and reduced survival included the presence of more than 25% atypical cells in dermal infiltrates, the size of neoplastic T-cells, the presence of coexistent interfollicular epidermotropism and presence of more than 10% Ki-67 positive cells. Presence of more than 10% blast cells was associated increased disease progression. In contrast, presence of prominent follicular mucinosis was associated with reduced disease progression and increased survival ( Table 3 ). The extent of perifollicular infiltrates, which had been used in our previous study as one of the parameters to differentiate between early and advanced plaque stage disease, 5 had no effect on prognosis and disease progression. Other factors that did not correlate with disease progression or survival were extent of folliculotropism, presence or absence of syringotropism, The observation that co-existent interfollicular epidermotropism is a risk factor for disease progression and reduced survival was unexpected and is at present unexplained. In 11 of 12 cases, with co-existent epidermotropism skin biopsies were obtained from characteristic FMF lesions in the face and none of these patients had concurrent skin lesions typical of classic MF.
Previous studies in classic MF showed that low numbers of admixed CD8+ T-cells are associated with disease progression and an inferior prognosis. [17] [18] [19] In the present study, such an association was not found. Notably, number of reactive CD8+ T-cells infiltrating into the follicular epithelium was very low, similar to the few or absent reactive CD8+ T-cells in the epidermis of early-stage classic MF.
Furthermore, we found that age at diagnosis and lack of complete response upon initial treatment were clinical prognostic factors associated with disease progression in plaque-stage FMF. Age is a well-reported prognostic factor in both classic MF and FMF, while complete response to initial treatment has been reported as a favorable prognostic factor in classic MF. 5, 6, [20] [21] [22] [23] In conclusion, the results of the present study show that FMF patients presenting with plaques represent a heterogeneous group and that a subgroup of these patients may have an indolent clinical course. Our results argue against the suggestion that all cases of FMF with plaques should be considered to have tumor-stage disease. They further show that histopathological examination is a valuable tool to differentiate between indolent and aggressive disease.
